Randomized non-inferiority trial to compare trimethoprim/sulfamethoxazole plus rifampicin versus linezolid for the treatment of MRSA infection | Zendy

Stephan Harbarth | Zendy; Elodie von Dach | Zendy; Léonardo Pagani | Zendy; Marina Macedo-Viñas | Zendy; Benedikt Huttner | Zendy; Flaminia Olearo | Zendy; Stéphane Emonet | Zendy; İlker Uçkay | Zendy

Open Access

Randomized non-inferiority trial to compare trimethoprim/sulfamethoxazole plus rifampicin versus linezolid for the treatment of MRSA infection

Author(s) -

Stephan Harbarth,

Elodie von Dach,

Léonardo Pagani,

Marina Macedo-Viñas,

Benedikt Huttner,

Flaminia Olearo,

Stéphane Emonet,

İlker Uçkay

Publication year - 2014

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dku352

Subject(s) - linezolid , medicine , trimethoprim , rifampicin , sulfamethoxazole , antibacterial agent , antibiotics , methicillin resistant staphylococcus aureus , randomized controlled trial , staphylococcus aureus , microbiology and biotechnology , tuberculosis , vancomycin , biology , pathology , bacteria , genetics

The therapeutic arsenal for MRSA infections is limited. The aim of this study was to assess the non-inferiority of a combination of trimethoprim/sulfamethoxazole plus rifampicin versus linezolid alone for the treatment of MRSA infection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research